Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Glioma 9Neuroblastoma 8Breast Neoplasms 6Neoplasms 5Thyroid Cancer, Papillary 4Sarcoma 4Neurofibroma, Plexiform 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Thyroid Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neurofibromatosis 1 3Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neuroendocrine Tumors 2Neoplasms by Site 2

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Thyroid Carcinoma, Anaplastic × CNS × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡